東北化学薬品 announced its results for the fiscal year ended September 2026, reporting ordinary income of ¥908 million, up 52.6% year on year and 10.7% above the preliminary forecast of ¥820 million. Ordinary income of ¥706 million is expected for the fiscal year ending September 2027.
東北化学薬品 announced ordinary income of ¥908 million for the fiscal year ended September 2026, a substantial increase from the same period of the previous year. This was above the market consensus estimate, with the increase reaching 52.6%.
In the earnings forecast for the next fiscal year released on the same day, ordinary income for the fiscal year ending September 2027 is expected to be ¥706 million, representing a 22.2% decline from the previous fiscal year.
Ordinary income of ¥349 million is expected for the interim period. This provides a breakdown of the full-year plan.
Investors are expected to closely monitor the subsequent earnings trend and progress toward achieving the outlook for the next fiscal year.